Aimmune Therapeutics, Inc. (NASDAQ:AIMT) is now up 19.88% compared to a 12-month low of $21.38. We have seen the price to move -2.81% lower and get settled at $25.63 on 01/11/2019. At recent session, it appeared stuck in a range of $25.511 to $26.6. This company shares are 114.59% off its target price of $55 and the current market capitalization stands at $1.63B. The recent change has given its price a 0.51% lead over SMA 50 and -38.98% deficit over its 52-week high. The stock witnessed 10.33% gains, 3.14% gains and -10.63% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AIMT’s volatility during a week at 6.07% and during a month it has been found around 6.34%.Aimmune Therapeutics, Inc. (AIMT) Top Holders
Institutional investors currently hold around $1.13 billion or 80.5% in AIMT stock. Look at its top three institutional owners. Price T Rowe Associates Inc /Md/ owns $120.09 million in Aimmune Therapeutics, Inc., which represents roughly 7.37% of the company’s market cap and approximately 10.61% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 3,982,580 shares of the stock are valued at $102.07 million. The third largest holder is Vanguard Group Inc, which currently holds $91.74 million worth of this stock and that ownership represents nearly 5.63% of its market capitalization.Aimmune Therapeutics, Inc. 13F Filings
At the end of September reporting period, 62 institutional holders increased their position in Aimmune Therapeutics, Inc. (NASDAQ:AIMT) by some 2,208,217 shares, 78 decreased positions by 4,086,089 and 30 held positions by 37,861,128. That puts total institutional holdings at 44,155,434 shares, according to SEC filings. The stock grabbed 21 new institutional investments totaling 289,054 shares while 29 institutional investors sold out their entire positions totaling 588,377 shares.Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Insider Trades
Multiple company employees have indulged in significant insider trading. Aimmune Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that General Manager, Europe Barrowcliffe Susan E. has sold 40,000 shares of Aimmune Therapeutics, Inc. (AIMT) in trading session dated Nov. 19, 2018. These shares are worth $1,201,600 and were traded at $30.04 each. The SEC filing shows that Dallas Jayson Donald Alexander performed a purchase of 3,650 shares. The President and CEO added these shares by way of transaction on Nov. 19, 2018. The company’s shares were assimilated at $27.56 per share worth to an investment of some $100,594 on account of Dallas Jayson Donald Alexander.
CFO, Bjerkholt Eric, purchased 1,600 common shares of Aimmune Therapeutics, Inc. (AIMT) in the open market. In a transaction dated Jun. 13, 2018, the shares were bought at an average price of $30.41, giving away a sum of $48,656. After this purchase, 19,485 common shares of AIMT are directly owned by the insider, with total stake valued at $499,401.
In the transaction dated Jun. 11, 2018, the great number of shares disposed came courtesy the President and CEO; Dilly Stephen George disposed a total of 29,457 shares at an average price of $30.83, amounting to approximately $908,159. The insider now directly owns 447,008 shares worth $11,456,815.Aimmune Therapeutics, Inc. (AIMT) Analyst Guide
Several analysts have released their opinion on Aimmune Therapeutics, Inc. (NASDAQ:AIMT), with 3 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 6 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.8 average brokerage recommendation.